These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30459162)

  • 21. Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men.
    Li XH; Xu Y; Yang K; Shi JJ; Zhang X; Yang F; Yuan H; Zhu X; Zhang YH; Wang JY; Yang Z
    J BUON; 2015; 20(5):1223-8. PubMed ID: 26537068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disparities in germline testing among racial minorities with prostate cancer.
    Weise N; Shaya J; Javier-Desloges J; Cheng HH; Madlensky L; McKay RR
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):403-410. PubMed ID: 34775478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review.
    Song SH; Byun SS
    Investig Clin Urol; 2021 May; 62(3):256-266. PubMed ID: 33943048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
    Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
    Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for familial and hereditary prostate cancer.
    Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
    Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India.
    Mandal RK; Gangwar R; Mandhani A; Mittal RD
    DNA Cell Biol; 2010 Apr; 29(4):183-90. PubMed ID: 20070155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
    Helfand BT; Xu J
    Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
    Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moving Prostate Cancer Polygenic Risk Scores from Research Towards Clinical Practice.
    Kearns JT; Helfand BT; Xu J
    Eur Urol Focus; 2022 Jul; 8(4):913-915. PubMed ID: 36055957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
    Wei Y; Wu J; Gu W; Qin X; Dai B; Lin G; Gan H; Freedland SJ; Zhu Y; Ye D
    Eur Urol; 2019 Sep; 76(3):280-283. PubMed ID: 31248605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression.
    Xu J; Shi Z; Wei J; Na R; Resurreccion WK; Wang CH; Sample C; Han M; Zheng SL; Cooney KA; Helfand BT; Isaacs WB
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):749-754. PubMed ID: 35149774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
    Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
    World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically Informed Prostate Cancer Screening.
    Arcot R; Morgan TM; Polascik TJ
    Urol Clin North Am; 2021 Aug; 48(3):373-386. PubMed ID: 34210492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic Markers in Prostate Cancer Decision Making.
    Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
    Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
    Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
    Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.